WELCOME TO VIVENTIA BIOTECH INC. QUICK LINKS

Viventia Biotech Inc. is a privately held biopharmaceutical company specializing in the discovery and development of a new generation of advanced monoclonal antibody products designed to offer safer, more beneficial therapies for those who suffer from cancer. Our lead product candidate Proxinium™ is in multiple clinical studies, including a Phase III clinical trial for the treatment of head and neck cancer.  Vicinium™ is in a Phase II clinical study for the treatment of bladder cancer, and VB6-845 is in a Phase I/II clinical trial for the treatment of solid tumors. Viventia is employing its novel monoclonal antibody discovery and development platforms to discover, validate and advance a portfolio of new antibody products based on proprietary oncology drug targets.

01/29//2008
Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data

06/11/2007
Viventia Biotech Initiates Patient Treatment For Phase I Trial Of VB6-845 Anti-Cancer Antibody
 



Copyright 2007 © Viventia Biotech Inc. All rights reserved.
The content of this site is for informational purposes only and is not intended to replace the advice of a health care professional.
Please consult your doctor if you have any questions regarding the information contained in this site.
Viventia, the Viventia logo, Proxinium, Vicinium, Unlock, Immunomine, Fusogenics, Power + Precision and Armed Antibodies are
Trade Marks of Viventia Biotech Inc.